Organization
Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
2 abstracts
Abstract
Health-related quality of life and economic burden in Chinese patients with cutaneous T-cell lymphoma.Org: Happy Life Tech Co., Ltd, Kyowa Kirin China Pharmaceutical, Department of Dermatology, Peking University First Hospital, Beijing, China, Department of Dermatology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College, Nanjing, China, Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China,
Abstract
Efficacy and safety of SY-3505, a third-generation ALK TKI, in ALK-positive advanced non-small cell lung cancer: Results from a phase I/II, multi-center study.Org: Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China, Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China, Department of Respiratory Medicine, West China Hospital of Sichuan University, Chengdu, China, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China,